117 related articles for article (PubMed ID: 20555269)
1. Detection of pancreatic adenocarcinoma using circulating fragments of fibrinogen.
Ward DG; Wei W; Buckels J; Taha AM; Hegab B; Tariciotti L; Salih R; Qi YQ; Martin A; Johnson PJ
Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1358-63. PubMed ID: 20555269
[TBL] [Abstract][Full Text] [Related]
2. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
3. [Application of serum protein profiling in diagnosis, prognosis and evaluation of curative effect of pancreatic adenocarcinoma].
Guo JH; Wang WJ; Liao P; Zhang CY; Jin DY; Lou WH; Zhang SC
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):33-6. PubMed ID: 20211064
[TBL] [Abstract][Full Text] [Related]
4. Standardized peptidome profiling of human serum for the detection of pancreatic cancer.
Zapico-Muñiz E; Farré-Viladrich A; Rico-Santana N; González-Sastre F; Mora-Brugués J
Pancreas; 2010 Nov; 39(8):1293-8. PubMed ID: 20924310
[TBL] [Abstract][Full Text] [Related]
5. [Pancreatic cancer screening: mission impossible?].
Bartel M; Friess H
Z Gastroenterol; 2006 Nov; 44(11):1181-2. PubMed ID: 17115361
[No Abstract] [Full Text] [Related]
6. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
8. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
Kang CM; Kim JY; Choi GH; Kim KS; Choi JS; Lee WJ; Kim BR
J Surg Res; 2007 Jun; 140(1):31-5. PubMed ID: 17418869
[TBL] [Abstract][Full Text] [Related]
9. Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer.
Matsubara J; Honda K; Ono M; Tanaka Y; Kobayashi M; Jung G; Yanagisawa K; Sakuma T; Nakamori S; Sata N; Nagai H; Ioka T; Okusaka T; Kosuge T; Tsuchida A; Shimahara M; Yasunami Y; Chiba T; Hirohashi S; Yamada T
Cancer Epidemiol Biomarkers Prev; 2011 Jan; 20(1):160-71. PubMed ID: 21148121
[TBL] [Abstract][Full Text] [Related]
10. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis.
Guo J; Wang W; Liao P; Lou W; Ji Y; Zhang C; Wu J; Zhang S
Cancer Sci; 2009 Dec; 100(12):2292-301. PubMed ID: 19775290
[TBL] [Abstract][Full Text] [Related]
11. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
[TBL] [Abstract][Full Text] [Related]
12. CA 19-9: not a magic marker for pancreatic cancer.
Daram SR
South Med J; 2006 Mar; 99(3):205. PubMed ID: 16553091
[No Abstract] [Full Text] [Related]
13. Diagnosis of pancreatic adenocarcinoma using protein chip technology.
Liu D; Cao L; Yu J; Que R; Jiang W; Zhou Y; Zhu L
Pancreatology; 2009; 9(1-2):127-35. PubMed ID: 19077463
[TBL] [Abstract][Full Text] [Related]
14. Serum determination of CA 19-9 in diagnosing pancreatic cancer: an obituary.
Pezzilli R; Casadei R; Calculli L; Santini D; Morselli-Labate AM;
Dig Liver Dis; 2010 Jan; 42(1):73-4. PubMed ID: 19473891
[No Abstract] [Full Text] [Related]
15. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
16. [A predictive model for pancreatic cancer using serum protein footprint map].
Long J; Di Y; Jin C; Yu XJ; Liu WW; Chen YM; Fu DL; Ni QX
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(22):1533-6. PubMed ID: 18956633
[TBL] [Abstract][Full Text] [Related]
17. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I
Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
19. Proteomic classification of pancreatic adenocarcinoma tissue using protein chip technology.
Scarlett CJ; Smith RC; Saxby A; Nielsen A; Samra JS; Wilson SR; Baxter RC
Gastroenterology; 2006 May; 130(6):1670-8. PubMed ID: 16697731
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
